Seres therapeutics to host conference call and webcast to discuss topline results from phase 2b study of ser-287 to treat mild-to-moderate ulcerative colitis

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast today at 8:30 a.m. et to discuss topline results from the phase 2b eco-reset study evaluating ser-287 in patients with mild-to-moderate ulcerative colitis (uc). to access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference id numbe
MCRB Ratings Summary
MCRB Quant Ranking